Lymphangioma - Lenfanjyomhttps://en.wikipedia.org/wiki/Lymphangioma
Lenfanjyom (Lymphangioma) se malfòmasyon nan sistèm lenfatik ki karakterize pa blesi ki se spò ki mens. Malfòmasyon sa yo ka parèt nenpòt laj epi yo ka enplike nenpòt pati nan kò a, men 90 % rive nan timoun ki gen mwens pase 2 ane epi yo souvan afekte tèt ak kou. Lymphangiom akeri yo ka soti apre chòk, enflamasyon, oswa blokaj lenfatik. Depi yo pa gen okenn chans pou yo vin malfezan, lenfanjyom yo anjeneral trete sèlman pou rezon kosmetik.

☆ AI Dermatology — Free Service
Nan rezilta Stiftung Warentest 2022 ki soti nan Almay, satisfaksyon konsomatè yo ak ModelDerm te sèlman yon ti kras pi ba pase ak konsiltasyon telemedsin peye.
References Recent Progress in Lymphangioma 34976885 
NIH
Lymphangioma, ki rele tou malformation lenfatik (LM), se yon maladi vaskilè ki prezan depi nesans. Li karakterize pa kwasans anòmal nan tisi lenfatik anvan ak apre nesans. Lymphangioma afekte apeprè 1 sou 2000 a 4000 moun, san okenn diferans enpòtan ant sèks oswa ras. Pifò ka yo (80‑90 %) dyagnostike anvan laj de an. Sentòm yo varye anpil, soti nan anfle lokalize rive nan gwo anomali nan kanal lenfatik yo, pafwa mennen nan anfle grav ki rele elefantiasis. Pou egzanp, lymphangioma nan kou a ak figi ka lakòz anfle figi, epi nan ka grav, defigire. Lè li afekte lang lan, li ka mennen nan kwasans twòp machwè ak dan ki pa alinye. Nan bouch ak kou, li ka koze pwoblèm pou respire ki menase lavi. Nan je yo, li ka lakoz pèt vizyon, mouvman je limite, po je tonbe, ak je gonfle. Patisipasyon manm yo ka lakoz anfle ak kwasans anòmal nan tisi ak zo. Anjeneral, timè a grandi tou dousman, men enfeksyon, chanjman òmòn, oswa blesi ka fè li grandi rapid, sa ki poze risk ki menase lavi e ki mande tretman ijan.
Lymphangioma (lymphatic malformation, LM), a congenital vascular disease, is a low-flow vascular abnormality in lymphatic diseases that is characterized by excessive growth of lymphatic tissue during prenatal and postpartum development. The incidence rate of LM is ~1:2000–4000, with no variation between genders and races. Most patients (80–90%) are diagnosed before the age of two. The clinical manifestations of lymphangioma are quite different among patients, varying from local swelling leading to superficial mass to a large area of diffuse infiltrating lymphatic channel abnormalities resulting in elephantiasis. Cervicofacial LM can cause facial elephantiasis, and in some severe cases, it can lead to serious disfigurement of the face. Tongue LM can lead to mandibular overgrowth and occlusal asymmetry, and oral and cervical LM can cause obstructive acute respiratory distress and life-threatening situations. Orbital LM may lead to decreased vision, decreased extraocular muscle movement, ptosis and exophthalmos. LM of the extremities can trigger swelling or gigantism, accompanied by overgrowth of soft tissue and bones. LM usually grows slowly and steadily, but under certain conditions, such as infection, hormonal changes or trauma, it can grow explosively and become a life-threatening disease requiring immediate treatment.
 Lymphangioma: Is intralesional bleomycin sclerotherapy effective? 22279495 
NIH
Nan etid retrospektif sa a, nou te revize 24 timoun ki te gen lymphangioma epi yo te trete ak piki solisyon bleomycin soti janvye 1999 rive desanm 2004. Pifò blesi yo (63 %) te disparèt nèt, 21 % te resevwa yon bon repons, epi 16 % pa t byen reponn. De pasyan te gen timè a tounen pita, epi de lòt te devlope absè kote yo te resevwa piki yo. Erezman, nou pa t wè okenn lòt gwo pwoblèm oswa efè segondè.
This is a retrospective study of 24 children diagnosed with lymphangioma and treated with intralesional injection of bleomycin aqueous solution from January 1999 to December 2004. Complete resolution was seen in 63% (15/24) of lesions, 21% (5/24) had good response and 16% (4/24) had poor response. The tumour recurred in 2 patients. Two other patients had abscess formation at the site of injection. No other serious complications or side effects were observed.
 Surgical Resection of Acquired Vulvar Lymphangioma Circumscriptum - Case reports 24665431 
NIH
Kalite prensipal lymphangioma yo se: lymphangioma circumscriptum, cavernous lymphangioma, cystic hygroma, lymphangioendothelioma. Yo reprezante apeprè 26 % timè vaskilè ki benign nan timoun, men yo pi ra lakay granmoun. Lymphangioma circumscriptum, ki se kalite ki pi souvan, montre kanal lenfatik ki soti sou po a, ki fòme vesik klè ki plen ak likid ki sanble ak anjandre krapo, ansanm ak anfle tisi yo. Li souvan parèt sou zòn ki gen anpil rezo lenfatik, tankou bra, kou, ak abdomèn. Yon fanm 71 an te vin nan klinik nou an ak anfle pèsistan sou janm li, boul woz sou jenital li, demanjezon, ak koule likid lenfatik. Nou te retire chirijikal tout boul yo ak yon pwosedi ki rele bilateral labiectomy, ki te fèt jiska nivo fascia Colles, pandan n ap prezève klitoris la ak fourchette.
The predominant types of lymphangioma are lymphangioma circumscriptum (LC), cavernous lymphangioma, cystic hygroma, and lymphangioendothelioma. These entities account for approximately 26% of benign vascular tumors in children but are rarer in adults. LC is the most common form of cutaneous lymphangioma and is characterized by superficial lymphatic ducts protruding through the epidermis. This condition results in clusters of clear fluid-filled vesicles resembling frog spawn and associated tissue edema. It is usually found on the proximal extremity, trunk, and axilla, which has an abundant lymphatic system. A 71-year-old female presented to our outpatient clinic with persistent edema of both lower limbs, clusters of pink labial papules, pruritus, and watery lymph oozing. We removed all the papules by performing bilateral major labiectomy down to the level of Colles' fascia, sparing the clitoris and fourchette.